Form 8-K

8-K — Transcode Therapeutics, Inc.

Accession: 0001104659-26-084617

Filed: 2026-07-17

Period: 2026-07-16

CIK: 0001829635

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Material Modifications to Rights of Security Holders

Item: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item: Financial Statements and Exhibits

Documents

8-K — tm2620727d1_8k.htm (Primary)

EX-3.1 — EXHIBIT 3.1 (tm2620727d1_ex3-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2620727d1_8k.htm · Sequence: 1

false

--12-31

0001829635

2026-07-16

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event

reported): July 16, 2026

TRANSCODE

THERAPEUTICS, INC.

(Exact name of registrant as specified in its

charter)

Delaware

001-40363

81-1065054

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

TransCode

Therapeutics, Inc.

Liberty Square, #2382

Boston, Massachusetts

02109

(Address

of principal executive offices, including zip code)

(857)

837-3099

(Registrant’s

telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since

Last Report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR

240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR

240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act.

Title of each class

Trading symbol(s)

Name of each exchange on which

registered

Common

Stock, par value $0.0001 per share

RNAZ

The Nasdaq

Capital Market

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging

growth company x

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 3.03

Material Modification to Rights of Securityholders.

To the extent required

by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated by reference into

this Item 3.03.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Amendment and Restatement of Certificate of Designation

previously disclosed, on March 2, 2026, TransCode Therapeutics, Inc. (the “Company”) filed

a Certificate of Designation of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock (the “Prior

Certificate”) with the Secretary of State of the State of Delaware in connection with the Exclusive Licensing Agreement dated as

of March 2, 2026, (the “Licensing Agreement”) by and between the Company and Unleash Immuno Oncolytics, Inc., a Delaware

corporation (“Unleash”), and that certain Equity Issuance and Registration Rights Agreement dated as of March 2, 2026,

(the “Unleash Registration Rights Agreement”) by and between the Company and Unleash.

July 16, 2026, upon obtaining the consent of a majority of the holders of the Company’s Series C Non-Voting Convertible Preferred

Stock, par value $0.0001 per share (“Series C Preferred Stock”), and the approval of the Company’s Board of Directors,

the Company filed an Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series C Non-Voting Convertible

Preferred Stock (the “Amended and Restated Certificate of Designation”) with the Secretary of State of the State of Delaware.

The Amended and Restated Certificate of Designation amended Section

6.3.3 of the Prior Certificate to increase the beneficial ownership limitation applicable to holders of Series C Preferred Stock from

4.99% to 9.99%. In addition, the Amended and Restated Certificate of Designation includes certain non-substantive revisions to the Prior

Certificate consisting solely of corrections to scrivener’s errors. The Amended and Restated Certificate of Designation effected

no other changes to the Prior Certificate other than the foregoing, and no additional securities were issued or sold in connection with

the filing.

The foregoing description of the Amended and Restated

Certificate of Designation does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended

and Restated Certificate of Designation, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated

herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number

Description

3.1

Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock of TransCode Therapeutics, Inc., dated July 16, 2026.

104

Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRANSCODE THERAPEUTICS, INC.

By:

/s/ Thomas A. Fitzgerald

Name:

Thomas A. Fitzgerald

Title:

Chief Financial Officer and Secretary

July 17, 2026

EX-3.1 — EXHIBIT 3.1

EX-3.1

Filename: tm2620727d1_ex3-1.htm · Sequence: 2

Exhibit 3.1

TransCode therapeutics,

inc.

AMENDED AND

RESTATED CERTIFICATE OF DESIGNATION OF PREFERENCES,

RIGHTS AND LIMITATIONS

SERIES C NON-VOTING

CONVERTIBLE PREFERRED STOCK

Pursuant to Section 151 of the

General Corporation Law of the State of Delaware

THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of TransCode Therapeutics,

Inc., a Delaware corporation, (the “Corporation”), that:

WHEREAS:

the Certificate of Incorporation of the Corporation, as amended (the “Certificate of Incorporation”), provides

for a class of its authorized stock known as Preferred Stock, consisting of 10,000,000 shares, $0.0001 par value per share (the “Preferred

Stock”), issuable from time to time in one or more series.

WHEREAS:

the Board of Directors of the Corporation (the “Board of Directors”), in accordance with the provisions of Section 151

of the General Corporation Law of the State of Delaware (the “DGCL”), previously adopted a resolution providing

for the creation of a series of the Corporation’s Preferred Stock which is designated as “Series C Non-Voting Convertible

Preferred Stock”, and the Certificate of Designation of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred

Stock was filed with the Secretary of State of the State of Delaware on March 2, 2026 (the “Prior Certificate of Designation”).

WHEREAS:

on July 15, 2026, the Board of Directors duly adopted the following resolution for purposes of amending and restating Section 6.3.3

of the Prior Certificate of Designation to increase the Beneficial Ownership Limitation from 4.99% to 9.99%.

WHEREAS:

the holders of a majority of the outstanding shares of the Corporation’s C Non-Voting Convertible Preferred Stock have approved

the following resolution to amend the Prior Certificate of Designation.

RESOLVED:

that, pursuant to authority conferred upon the Board of Directors by the Certificate of Incorporation, the Certificate of Designation

of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock that fixes the relative designations,

powers, preferences and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions

thereof, of such shares of Series C Non-Voting Convertible Preferred Stock, in addition to any provisions set forth in the Certificate

of Incorporation that are applicable to the Series C Non-Voting Convertible Preferred Stock, is hereby amended and restated as follows:

TERMS OF SERIES

C NON-VOTING CONVERTIBLE PREFERRED STOCK

Definitions. For the purposes hereof, the following terms shall have the following meanings:

“Business Day” means

any day other than a Saturday, Sunday or other day on which banks in New York, NY, are authorized or obligated by Law to be closed.

“Closing Sale Price”

means, for any security as of any date, the last closing trade price for such security immediately prior to 4:00 p.m., New York

City time, on the principal Trading Market where such security is listed or traded, as reported by Bloomberg, L.P. (or an equivalent,

reliable reporting service), or if the foregoing do not apply, the last trade price of such security in the over-the-counter market on

the electronic bulletin board for such security as reported by Bloomberg, L.P., or, if no last trade price is reported for such security

by Bloomberg, L.P., the average of the bid prices of any market makers for such security as reported on the OTCID Basic Market by OTC

Markets Group, Inc. If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases,

the Closing Sale Price of such security on such date shall be the fair market value as determined in good faith by the Board of Directors.

“Commission” means the

United States Securities and Exchange Commission.

“Common Stock” means

the Corporation’s common stock, par value $0.0001 per share, and stock of any other class of securities into which such securities

may hereafter be reclassified or changed.

“Conversion Shares” means

the shares of Common Stock issuable upon conversion of the shares of Series C Non-Voting Convertible Preferred Stock in accordance with

the terms hereof.

“Exchange Act” means

the Securities Exchange Act of 1934.

“Holder” means a holder

of shares of Series C Non-Voting Convertible Preferred Stock.

“Person” means an individual

or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock

company, government (or an agency or subdivision thereof) or other entity of any kind.

“Equity Issuance and Registration Rights

Agreement” means that certain Equity Issuance and Registration Rights Agreement, dated as of March 2, 2026, by and

between the Corporation and Unleash Immuno Oncolytics, Inc., a Delaware corporation (“Unleash”).

“Trading Day” means a

day on which the principal Trading Market is open for business.

“Trading Market” means

any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE

American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or

any successors to any of the foregoing).

Designation, Amount and Par Value. The series of Preferred Stock shall be designated as the Corporation’s Series C

Non-Voting Convertible Preferred Stock (the “Series C Non-Voting Preferred Stock”), and the number of shares

so designated to be Series C Non-Voting Preferred Stock shall be 1,214,204. Each share of Series C Non-Voting Preferred Stock shall have

a par value of $0.0001 per share.

Dividends. Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of the Series C Non-Voting

Preferred Stock (on an as-if-converted-to-Common-Stock basis, without regard to the Beneficial Ownership Limitation (as defined below))

equal to and in the same form, and in the same manner, as dividends (other than dividends on shares of the Common Stock payable in the

form of Common Stock) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends payable in the

form of Common Stock) are paid on shares of the Common Stock; provided, however, in no event shall Holders of Series C Non-Voting Preferred

Stock be entitled to receive the “rights” distributed pursuant to that certain Contingent Value Rights Agreement effective

as of October 8, 2025, by and between the Corporation and Vstock Transfer, LLC, as may be amended from time to time (the “CVR

Agreement”), or any amounts paid under the CVR Agreement.

Voting Rights.

4.1

Except as otherwise provided herein or as otherwise required by the DGCL, the Series C Non-Voting Preferred Stock shall have no

voting rights. However, as long as any shares of Series C Non-Voting Preferred Stock are outstanding, the Corporation shall not, without

the affirmative vote of the holders of a majority of the then outstanding shares of the Series C Non-Voting Preferred Stock: (A) alter

or change adversely the powers, preferences or rights given to the Series C Non-Voting Preferred Stock or alter or amend this Certificate

of Designation, amend or repeal any provision of, or add any provision to, the Certificate of Incorporation or Amended and Restated Bylaws

of the Corporation, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any

series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions

provided for the benefit of, the Series C Non-Voting Preferred Stock, regardless of whether any of the foregoing actions shall be by means

of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise,

or (B) issue further shares of Series C Non-Voting Preferred Stock or increase or decrease (other than by conversion) the number

of authorized shares of Series C Non-Voting Preferred Stock. Holders of shares of Common Stock acquired upon the conversion of shares

of Series C Non-Voting Preferred Stock shall be entitled to the same voting rights as each other holder of Common Stock, except that such

holders may not vote such shares upon the proposal for Stockholder Approval pursuant to the Equity Issuance and Registration Rights Agreement

in accordance with Rule 5635 of the listing rules of The Nasdaq Stock Market LLC.

4.2

Any vote required or permitted under Section 4.1 may be taken at a meeting of the Holders or through the execution

of an action by written consent in lieu of such meeting, provided that the consent is executed by Holders representing at least a majority

of the outstanding shares of Series C Non-Voting Preferred Stock.

Rank; Liquidation.

5.1

Each series of the Series C Non-Voting Preferred Stock shall rank on parity with (a) the Common Stock and (b) the series of the

Corporation’s Preferred Stock, par value $0.0001 per share, which is designated as “Series A Non-Voting Convertible Preferred

Stock,” (the “Series A Non-Voting Preferred Stock”), and (c) the series of the Corporation’s Preferred

Stock, par value $0.0001 per share, which is designated as “Series B Non-Voting Convertible Preferred Stock” (the “Series

B Non-Voting Preferred Stock”), as to distributions of assets upon liquidation, dissolution or winding up of the Corporation,

whether voluntarily or involuntarily. As used herein, the Series A Non-Voting Preferred Stock, the Series B Non-Voting Preferred Stock

and the Series C Non-Voting Preferred Stock are referred to collectively as the “Non-Voting Preferred Stock”.

5.2

Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a “Liquidation”),

each Holder shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that a holder

of Common Stock would receive if the Series C Non-Voting Preferred Stock, and the other Non-Voting Preferred Stock, were fully converted

(disregarding for such purpose any Beneficial Ownership Limitation) to Common Stock which amounts shall be paid pari passu

with all holders of Common Stock, plus an additional amount equal to any dividends accrued on but unpaid to such shares. If, upon any

such Liquidation, the assets of the Corporation shall be insufficient to pay the Holders of shares of the Series C Non-Voting Preferred

Stock and holders of the other Non-Voting Preferred Stock and Common Stock the amount required under the preceding sentence, then all

remaining assets of the Corporation shall be distributed ratably to the Holders of the Series C Non-Voting Preferred Stock and the holders

of the other Non-Voting Preferred Stock and the Common Stock in accordance with the respective amounts that would be payable on all such

securities if all amounts payable thereon were paid in full. For the avoidance of any doubt, a Fundamental Transaction shall not be deemed

a Liquidation unless the Corporation or the Board of Directors expressly declares that such Fundamental Transaction shall be treated as

if it were a Liquidation.

Conversion.

6.1

Conversion at Option of Holder.

6.1.1

Subject to Section 6.3, each share of Series C Non-Voting Preferred Stock then outstanding shall be convertible, at

any time and from time to time following 5:00 p.m. Eastern time on the third Business Day after the date that the Corporation’s

stockholders approve the conversion of the Series C Non-Voting Preferred Stock into shares of Common Stock in accordance with the listing

rules of the Nasdaq Stock Market (the “Stockholder Approval”), in each case at the option of the Holder thereof,

into a number of shares of Common Stock based upon the applicable Conversion Ratio, subject in all cases to any applicable Beneficial

Ownership Limitation (each, an “Optional Conversion”).

6.1.2

Holders shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as Annex A

(a “Notice of Conversion”), duly completed and executed. Provided the Corporation’s transfer agent is

participating in the Depository Trust Company (“DTC”) Fast Automated Securities Transfer program, the Notice

of Conversion may specify, at the Holder’s election, whether the applicable Conversion Shares shall be credited to the account of

the Holder’s prime broker with DTC through its Deposit Withdrawal Agent Commission system (a “DWAC Delivery”).

The date on which an Optional Conversion shall be deemed effective (the “Conversion Date”) shall be the Trading

Day that the Notice of Conversion, completed and executed, is sent via email to, and received during regular business hours by, the Corporation;

provided, that the original certificate(s) (if any) representing such shares of Series C Non-Voting Preferred Stock being converted, duly

endorsed, and the accompanying Notice of Conversion, are received by the Corporation within two (2) Trading Days thereafter. In all

other cases, the Conversion Date shall be defined as the Trading Day on which the original certificate(s) (if any) representing such shares

of Series C Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the

Corporation. The calculations set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error.

6.2

Conversion Ratio. The “Conversion Ratio” for each share of Series C Non-Voting Preferred Stock

shall be one (1) share of Common Stock issuable upon the conversion (the “Conversion”) of each share of Series

C Non-Voting Preferred Stock, subject to adjustment as provided herein.

6.3

Beneficial Ownership Limitation.

6.3.1

The Corporation shall not effect any conversion of any share of Series C Non-Voting Preferred Stock, and a Holder shall not have

the right to convert any portion of the Series C Non-Voting Preferred Stock pursuant to Section 6.1, to the extent that, after

giving effect to such attempted conversion set forth on an applicable Notice of Conversion, such Holder (or any of such Holder’s

affiliates or any other Person who would be a beneficial owner of Common Stock beneficially owned by the Holder for purposes of Section 13(d)

of the Exchange Act and the applicable rules and regulations of the Commission, including any “group” of which the Holder

is a member (the foregoing, “Attribution Parties”)) would beneficially own a number of shares of Common Stock

in excess of the Beneficial Ownership Limitation. Except as set forth in the preceding sentence, for purposes of this Section 6.3,

beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the applicable rules and regulations

of the Commission, and the terms “beneficial ownership” and “beneficially own” have the meanings ascribed to such

terms therein. In addition, for purposes hereof, “group” has the meaning set forth in Section 13(d) of the Exchange Act

and the applicable rules and regulations of the Commission.

6.3.2

For purposes of this Section 6.3, in determining the number of outstanding shares of Common Stock, a Holder may rely on

the number of outstanding shares of Common Stock as stated in the most recent of the following: (A) the Corporation’s most

recent periodic or annual filing with the Commission, as the case may be, (B) a more recent public announcement by the Corporation

that is filed with the Commission, or (C) a more recent notice by the Corporation or the Corporation’s transfer agent to the

Holder setting forth the number of shares of Common Stock then outstanding. Upon the written request of a Holder (which may be by email),

the Corporation shall, within two (2) Trading Days thereof, confirm in writing to such Holder (which may be via email) the number

of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving

effect to any actual conversion or exercise of securities of the Corporation, including shares of Series C Non-Voting Preferred Stock,

by such Holder or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was last publicly

reported or confirmed to the Holder.

6.3.3

The “Beneficial Ownership Limitation” shall initially be set at 9.99% of outstanding shares of Common

Stock for each Holder and its Attribution Parties. Notwithstanding the foregoing, at any time following the earliest to occur of (A) the

receipt of the Stockholder Approval and (B) the consummation of a Fundamental Transaction, the Holder may waive and/or change the Beneficial

Ownership Limitation effective upon written notice to the Corporation; provided, that to the extent such waiver or change is solely

permitted under subsections (A) or (B) of this Section 6.3.3, such notice must be delivered not less than sixty (60) days prior to the

effectiveness of such waiver and/or change. The Holder may reinstitute a Beneficial Ownership Limitation at any time thereafter effective

immediately upon written notice to the Corporation. Notwithstanding any other provision of this Certificate of Designation, prior to receipt

by the Corporation of the Stockholder Approval, the Corporation shall not be required to effect a Conversion to the extent such Conversion

would cause the Corporation to violate Nasdaq Listing Rule 5635.

6.4

Mechanics of Conversion.

6.4.1

Delivery of Certificate or Electronic Issuance. Upon Conversion not later than two (2) Trading Days after the applicable

Conversion Date, or if the Holder requests the issuance of physical certificate(s), two (2) Trading Days after receipt by the Corporation

of the original certificate(s) representing such shares of Series C Non-Voting Preferred Stock being converted, duly endorsed, and the

accompanying Notice of Conversion (the “Share Delivery Date”), the Corporation shall either: (a) deliver,

or cause to be delivered, to the converting Holder a physical certificate or certificates representing the number of Conversion Shares

being acquired upon the conversion of shares of Series C Non-Voting Preferred Stock, or (b) in the case of a DWAC Delivery (if so

requested by the Holder), electronically transfer such Conversion Shares by crediting the account of the Holder’s prime broker with

DTC through its DWAC system. If in the case of any Notice of Conversion such certificate or certificates for the Conversion Shares are

not delivered to or as directed by or, in the case of a DWAC Delivery, such shares are not electronically delivered to or as directed

by, the applicable Holder by the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind such Notice of Conversion

by written notice to the Corporation at any time on or before its receipt of such certificate or certificates for Conversion Shares or

electronic receipt of such shares, as applicable, in which event the Corporation shall promptly return to such Holder any original Series

C Non-Voting Preferred Stock certificate delivered to the Corporation and such Holder shall promptly return to the Corporation any Common

Stock certificates or otherwise direct the return of any shares of Common Stock delivered to the Holder through the DWAC system, representing

the shares of Series C Non-Voting Preferred Stock unsuccessfully tendered for conversion to the Corporation, and for all purposes the

conversion shall not be deemed to have occurred.

6.4.2

Obligation Absolute. Subject to Section 6.3 and subject to Holder’s right to rescind a Notice of Conversion

pursuant to Section 6.4.1, the Corporation’s obligation to issue and deliver the Conversion Shares upon conversion of

Series C Non-Voting Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or

inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against

any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged

breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder

or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such

Holder in connection with the issuance of such Conversion Shares. Subject to Section 6.3 and subject to Holder’s right to

rescind a Notice of Conversion pursuant to Section 6.4.1, in the event a Holder shall elect to convert any or all of its Series

C Non-Voting Preferred Stock, the Corporation may not refuse conversion based on any claim that such Holder or anyone associated or affiliated

with such Holder has been engaged in any violation of law, agreement or for any other reason, unless an injunction from a court, on notice

to Holder, restraining and/or enjoining conversion of all or part of the Series C Non-Voting Preferred Stock of such Holder shall have

been sought and obtained by the Corporation, and the Corporation posts a surety bond for the benefit of such Holder in the amount of 150%

of the value of the Conversion Shares into which would be converted the Series C Non-Voting Preferred Stock which is subject to such injunction,

which bond shall remain in effect until the completion of arbitration/litigation of the underlying dispute and the proceeds of which shall

be payable to such Holder to the extent it obtains judgment. In the absence of such injunction, the Corporation shall, subject to Section

6.3 and subject to Holder’s right to rescind a Notice of Conversion pursuant to Section 6.4.1, issue Conversion

Shares upon a properly noticed conversion.

6.4.3

Reservation of Shares Issuable Upon Conversion. The Corporation covenants that at all times it will reserve and keep available

out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series C Non-Voting

Preferred Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holders of the Series

C Non-Voting Preferred Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account

the adjustments of Section 7) upon the conversion of all outstanding shares of Series C Non-Voting Preferred Stock. The Corporation

covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid

and non-assessable.

6.4.4

Fractional Shares. No fractional shares of Common Stock shall be issued upon conversion of the Series C Non-Voting Preferred

Stock, no certificates or scrip for any such fractional shares shall be issued and no cash shall be paid for any such fractional shares.

Any fractional shares of Common Stock that a Holder of Series C Non-Voting Preferred Stock would otherwise be entitled to receive shall

be aggregated with all fractional shares of Common Stock issuable to such Holder and any remaining fractional shares shall be rounded

up to the nearest whole share. Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis

of the total number of shares of Series C Non-Voting Preferred Stock the Holder is at the time converting into Common Stock and the aggregate

number of shares of Common Stock issuable upon such conversion.

6.4.5

Transfer Taxes. The issuance of certificates for shares of the Common Stock upon conversion of the Series C Non-Voting Preferred

Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue

or delivery of such certificates, provided that the Corporation shall not be required to pay any tax that may be payable in respect of

any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the registered

Holder(s) of such shares of Series C Non-Voting Preferred Stock and the Corporation shall not be required to issue or deliver such certificates

unless and until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall

have established to the satisfaction of the Corporation that such tax has been paid.

6.5

Status as Stockholder. Upon each Conversion Date, (A) the shares of Series C Non-Voting Preferred Stock being converted

shall be deemed converted into shares of Common Stock and (B) the Holder’s rights as a holder of such converted shares of Series

C Non-Voting Preferred Stock shall cease and terminate, excepting only the right to receive certificates for such shares of Common Stock

and to any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation

to comply with the terms of this Certificate of Designation. In all cases, the Holder shall retain all of its rights and remedies for

the Corporation’s failure to convert Series C Non-Voting Preferred Stock. In no event shall the Series C Non-Voting Preferred Stock

convert into shares of Common Stock prior to the Stockholder Approval.

Certain Adjustments.

7.1

Stock Dividends and Stock Splits. If the Corporation, at any time while this Series C Non-Voting Preferred Stock is outstanding:

(A) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock (which, for avoidance

of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion of this Series C Non-Voting Preferred

Stock) with respect to the then outstanding shares of Common Stock; (B) subdivides outstanding shares of Common Stock into a larger

number of shares; or (C) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number

of shares, then the Conversion Ratio shall be multiplied by a fraction of which the numerator shall be the number of shares of Common

Stock (excluding any treasury shares of the Corporation) outstanding immediately after such event and of which the denominator shall be

the number of shares of Common Stock outstanding immediately before such event (excluding any treasury shares of the Corporation). Any

adjustment made pursuant to this Section 7.1 shall become effective immediately after the record date for the determination

of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the

case of a subdivision or combination.

7.2

Fundamental Transaction. If, at any time while this Series C Non-Voting Preferred Stock is outstanding, (A) the Corporation

effects any merger or consolidation of the Corporation with or into another Person or any stock sale to, or other business combination

(including, without limitation, a reorganization, recapitalization, spin-off, share exchange or scheme of arrangement) with or into another

Person, (B) the Corporation effects any sale, lease, transfer or exclusive license of all or substantially all of its assets in one

transaction or a series of related transactions, (C) any tender offer or exchange offer (whether by the Corporation or another Person)

is completed pursuant to which more than 20% of the Common Stock not held by the Corporation or such Person is exchanged for or converted

into other securities, cash or property, or (D) the Corporation effects any reclassification of the Common Stock or any compulsory

share exchange pursuant (other than as a result of a dividend, subdivision or combination covered by Section 7.1) to which

the Common Stock is effectively converted into or exchanged for other securities, cash or property (in any such case, a “Fundamental

Transaction”), then, upon any subsequent conversion of this Series C Non-Voting Preferred Stock, the Holders shall have

the right to receive, in lieu of the right to receive Conversion Shares, for each Conversion Share that would have been issuable upon

such conversion immediately prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property

as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such

Fundamental Transaction, the holder of one share of Common Stock (the “Alternate Consideration”). For purposes

of any such subsequent conversion, the determination of the Conversion Ratio shall be appropriately adjusted to apply to such Alternate

Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction.

If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then

each Holder shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Series C Non-Voting

Preferred Stock following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor

to the Corporation or surviving entity in such Fundamental Transaction shall file a new certificate of designations at the effective time

of such Fundamental Transaction, with the same terms and conditions and issue to the Holders new preferred stock consistent with the foregoing

provisions and evidencing the Holders’ right to convert such preferred stock into Alternate Consideration. The terms of any agreement

to which the Corporation is a party and pursuant to which a Fundamental Transaction is effected shall include terms requiring any such

successor or surviving entity to comply with the provisions of this Section 7.2 and ensuring that this Series C Non-Voting

Preferred Stock (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental

Transaction. The Corporation shall cause to be delivered to each Holder, at its last address as it shall appear upon the stock books of

the Corporation, written notice of any Fundamental Transaction at least 20 calendar days prior to the date on which such Fundamental

Transaction is expected to become effective or close. Notwithstanding anything to the contrary herein, the Corporation’s disposition

of certain assets pursuant to the CVR Agreement shall not constitute a Fundamental Transaction.

7.3

Calculations. All calculations under this Section 7 shall be made to the nearest cent or the nearest share,

as the case may be. For purposes of this Section 7, the number of shares of Common Stock deemed to be issued and outstanding

as of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued

and outstanding.

Transfer. A Holder may transfer any shares of Series C Non-Voting Preferred Stock together with the accompanying rights

set forth herein, held by such Holder without the consent of the Corporation; provided that such transfer is in compliance with applicable

securities laws. The Corporation shall in good faith (a) do and perform, or cause to be done and performed, all such further acts

and things, and (b) execute and deliver all such other agreements, certificates, instruments and documents, in each case, as any

Holder of Series C Non-Voting Preferred Stock may reasonably request in order to carry out the intent and accomplish the purposes of this

Section 8. The transferee of any shares of Series C Non-Voting Preferred Stock shall be subject to the Beneficial Ownership

Limitation applicable to the transferor as of the time of such transfer.

Series C Non-Voting Preferred Stock Register. The Corporation shall maintain at its principal executive offices (or such

other office or agency of the Corporation as it may designate by notice to the Holders in accordance with Section 11), a register

for the Series C Non-Voting Preferred Stock, in which the Corporation shall record (a) the name, address, and electronic mail address

of each holder in whose name the shares of Series C Non-Voting Preferred Stock have been issued and (b) the name, address, and electronic

mail address of each transferee of any shares of Series C Non-Voting Preferred Stock. The Corporation may deem and treat the registered

Holder of shares of Series C Non-Voting Preferred Stock as the absolute owner thereof for the purpose of any conversion thereof and for

all other purposes. The Corporation shall keep the register open and available at all times during business hours for inspection by any

holder of Series C Non-Voting Preferred Stock or his, her or its legal representatives.

10.

Notices. Any notice required or permitted by the provisions of this Certificate of Designation to be given to a Holder of

shares of Series C Non-Voting Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of

the Corporation, or given by electronic communication in compliance with the provisions of the Delaware General Corporation Law, and shall

be deemed sent upon such mailing or electronic transmission.

11.

Book-Entry; Certificates. The Series C Non-Voting Preferred Stock will be issued in book-entry form; provided that, if a

Holder requests that such Holder’s shares of Series C Non-Voting Preferred Stock be issued in certificated form, the Corporation

will instead issue a stock certificate to such Holder representing such Holder’s shares of Series C Non-Voting Preferred Stock.

To the extent that any shares of Series C Non-Voting Preferred Stock are issued in book-entry form, references herein to “certificates”

shall instead refer to the book-entry notation relating to such shares.

12.

Waiver. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall

not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate

of Designation or a waiver by any other Holders, other than as expressly set forth herein. The failure of the Corporation or a Holder

to insist upon strict adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver

or deprive that party (or any Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate

of Designation. Any waiver by the Corporation or a Holder must be in writing. Notwithstanding any provision in this Certificate of Designation

to the contrary, any provision contained herein and any right of the Holders of Series C Non-Voting Preferred Stock granted hereunder

may be waived as to all shares of Series C Non-Voting Preferred Stock (and the Holders thereof) upon the written consent of the Holders

of not less than a majority of the shares of Series C Non-Voting Preferred Stock then outstanding, provided, however, that the Beneficial

Ownership Limitation applicable to a Holder, and any provisions contained herein that are related to such Beneficial Ownership Limitation,

cannot be modified, waived or terminated without the consent of such Holder, provided further, that any proposed waiver that would, by

its terms, have a disproportionate and materially adverse effect on any Holder shall require the consent of such Holder(s).

13.

Severability. Whenever possible, each provision hereof shall be interpreted in a manner as to be effective and valid under

applicable law, but if any provision hereof is held to be prohibited by or invalid under applicable law, then such provision shall be

ineffective only to the extent of such prohibition or invalidity, without invalidating or otherwise adversely affecting the remaining

provisions hereof.

14.

Status of Converted Series C Non-Voting Preferred Stock. If any shares of Series C Non-Voting Preferred Stock shall be converted

or redeemed by the Corporation, such shares shall, to the fullest extent permitted by applicable law, be retired and cancelled upon such

acquisition, and shall not be reissued as shares of Series C Non-Voting Preferred Stock. Any share of Series C Non-Voting Preferred Stock

so acquired shall, upon its retirement and cancellation, and upon the taking of any action required by applicable law, resume the status

of authorized but unissued shares of preferred stock and shall no longer be designated as Series C Non-Voting Preferred Stock.

[Remainder of Page Intentionally Left Blank]

WITNESS WHEREOF, TransCode Therapeutics, Inc. has caused this Amended and Restated Certificate of Designation of Preferences,

Rights and Limitations of Series C Non-Voting Convertible Preferred Stock to be duly executed by its Chief Executive Officer on July 16,

2026.

TRANSCODE THERAPEUTICS, INC.

By:

/s/ Philippe P. Calais

Name: Philippe P. Calais

Title: Chief Executive Officer

ANNEX A

NOTICE OF CONVERSION

(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER

TO CONVERT SHARES OF SERIES C CONVERTIBLE PREFERRED STOCK)

The undersigned Holder hereby irrevocably elects to convert the number

of shares of Series C Non-Voting Convertible Preferred Stock indicated below, represented in book-entry form, into shares of common stock,

par value $0.0001 per share, (the “Common Stock”) of TransCode Therapeutics, Inc., a Delaware corporation, (the

“Corporation”) as of the date written below. If securities are to be issued in the name of a Person other than

the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Capitalized terms utilized but not defined

herein shall have the meaning ascribed to such terms in that certain Amended and Restated Certificate of Designation of Preferences, Rights

and Limitations of Series C Non-Voting Convertible Preferred Stock (the “Certificate of Designation”) filed

by the Corporation with the Secretary of State of the State of Delaware on July 16, 2026.

As of the date hereof, the number of shares of Common Stock beneficially

owned by the undersigned Holder (together with such Holder’s Attribution Parties), including the number of shares of Common Stock

issuable upon conversion of the Series C Non-Voting Convertible Preferred Stock subject to this Notice of Conversion, but excluding the

number of shares of Common Stock which are issuable upon (A) conversion of the remaining, unconverted Series C Non-Voting Convertible

Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B) exercise or conversion of the unexercised

or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder or any of

its Attribution Parties that are subject to a limitation on conversion or exercise, is _____. For purposes hereof, beneficial ownership

shall be calculated in accordance with Section 13(d) of the Exchange Act and the applicable regulations of the Commission. In addition,

for purposes hereof, “group” has the meaning set forth in Section 13(d) of the Exchange Act and the applicable regulations

of the Commission.

CONVERSION CALCULATIONS:

Date to Effect Conversion:

Number of shares of Series C Non-Voting Convertible Preferred Stock owned prior to Conversion:

Number of shares of Series C Non-Voting Convertible Preferred Stock to be Converted:

Number of shares of Common Stock to be Issued:

Address for delivery of physical certificates:

For DWAC Delivery, please provide the following:

Broker No.:

Account No.:

[HOLDER]

By:

Name:

Title:

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Jul. 16, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 16, 2026

Current Fiscal Year End Date

--12-31

Entity File Number

001-40363

Entity Registrant Name

TRANSCODE

THERAPEUTICS, INC.

Entity Central Index Key

0001829635

Entity Tax Identification Number

81-1065054

Entity Incorporation, State or Country Code

Entity Address, Address Line One

Liberty Square

Entity Address, Address Line Two

#2382

Entity Address, City or Town

Boston

Entity Address, State or Province

Entity Address, Postal Zip Code

02109

City Area Code

857

Local Phone Number

837-3099

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.0001 per share

Trading Symbol

RNAZ

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name:

dei_CurrentFiscalYearEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:gMonthDayItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration